198 results on '"Knutson F"'
Search Results
2. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment
3. An Enthronement Ritual at Ugarit
4. World apheresis registry 2003–2007 data
5. Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth media supplemented with 10% human platelet lysate
6. QUALITY OF PATHOGEN AND LEUKOCYTE INACTIVATED RBC COMPARED TO CONVENTIONAL AND GAMMA IRRADIATED RBC: 3C-S14–04
7. AN EVALUATION OF THE BLOOD DONOR HEALTH QUESTIONNAIRE (DHQ) IN SWEDEN 2012: 2A-S05-05
8. Evaluation of In Vitro Platelet Function in INTERCEPT Treated Platelet Units Containing 8 × 1011 Platelets Using the INTERCEPT Platelet Processing Set with Dual Storage Containers: SP25
9. Prophylactic platelet transfusions
10. PANORAMA OF ADVERSE EVENTS DURING CYTAPHERESIS: O127 (S.4-5)
11. Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma
12. Characteristics of Liquid Plasma Treated with the INTERCEPT Blood System for Pathogen Inactivation and Stored at 4°C for 14 Days: SP26
13. Frequency of Prophylactic Transfusion Failure: A Novel Outcome to Evaluate Platelet Components Stored More than 5 Days: S54-030D
14. Photochemical pathogen inactivation of human serum enables its large-scale application in clinical cell transplantation
15. Safety of Transfusions in Pediatric Patients with Platelet Components Prepared with Photochemical Treatment (INTERCEPT Blood SystemTM): S43-020E
16. Unexpected effects of donor gender on the storage of liquid plasma
17. PLASMA COMPONENTS AVAILABLE FOR IMMEDIATE TRANSFUSION: P-667
18. SUCCESSFUL TREATMENT OF A PATIENT WITH AML AND A CLOSTRIDIUM PERFRINGENS SEPSIS WITH MASSIVE HEMOLYSIS: P-484
19. In Vitro Evaluation Of Buffy-Coat Platelet Concentrations Prepared With Orbisac Buffy-Coat System, Treated With Intercept Blood System: SP117
20. Improved maintenance of 2,3 DPG and ATP in RBCs stored in a modified additive solution
21. Increased mucosal synthesis of rheumatoid factor (RF) in coeliac disease
22. Increased anticoagulant osmolality improves separation of leukocytes from red blood cells (RBC)
23. Pre-separation storage of whole blood: the effect of temperature on red cell 2,3-diphosphoglycerate and myeloperoxidase in plasma
24. Distribution of indications and procedures within the framework of centers participating in the WAA apheresis registry
25. Distribution of indications and procedures within the framework of centers participating in the WAA apheresis registry
26. Adverse events in apheresis : an update of the WAA registry data
27. Adverse events in apheresis: An update of the WAA registry data
28. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
29. Caractéristiques du plasma traité par Intercept™ Blood System pour l’inactivation des agents pathogènes et conservé à 4°C pendant 14jours
30. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVAphotochemical treatment
31. Vox sanguinis / Logistics of platelet concentrateses
32. Fehldiagnose HIT bei einem thrombozytopenen Patienten – Fallbeschreibung mit Anmerkungen zur Differenzialdiagnose*
33. Panorama of adverse events during cytapheresis
34. AN EVALUATION OF THE BLOOD DONOR HEALTH QUESTIONNAIRE (DHQ) IN SWEDEN 2012
35. Prophylactic platelet transfusions.
36. An Active Hemovigilance Program To Characterize the Safety Profile of 16,631 Platelet Components Prepared With Photochemical Pathogen Inactivation Treatment Transfused in Routine Clinical Practice
37. World apheresis registry 2003-2007 data.
- Abstract
Objectives: Seventy-five centers from many countries have applied for a login code to the WAA apheresis registry. Fifteen centers from 7 countries have been actively entering data at the internet site from 2003 until 2007. We report on data from the registry so far. Methods: This is a web-based registry. A link is available from the WAA homepage (www.worldapheresis.org). So far data from 2013 patients (12,448 procedures) have been included. A median of 6 treatments have been performed (range 1–140). Mean age 51 years (range 1–94 years; 45% women). Seven percent of the patients were
![]("http://www.sciencedirect.com/scidirimg/entities/2a7d.gif")
21 years and 4% were 16 years. Results: The purpose of the apheresis procedure was therapeutic in 67% and retrieval of blood components in 33%. Main indications: neurological and hematological diseases, lipidapheresis and stemcell collection (autologous, and some allogeneic). Blood access: peripheral vessels (71%), central dialysis catheter through jugular (6.5%) or subclavian veins (6.7%), femoral vein (8%) and AV fistula (4%). ACD was used for anticoagulation in 73% of the procedures. Albumin was mainly used as replacement fluid. Adverse events (AE) were registered in 5.7% of the procedures. AE was graded as mild (2.5%), moderate (2.7%) or severe (0.5%). No death occurred due to treatment. The procedures were interrupted in 2.6%. Most frequent AEs were blood access problems (29%), tingling around the mouth (20%), hypotension (18%), and urticaria (9%). There were significant differences between the centers regarding mild and moderate AEs. Data indicate that centers using continuous infusion of calcium had fewer AEs. Conclusion: There was a limited number of severe AEs. Centers use various standard procedures for apheresis. By learning from the experience of others the treatment quality will improve further. In the near future, an update of the regist
38. Panorama of adverse events during cytapheresis
39. Unexpected effects of donor gender on the storage of liquid plasma.
40. Caractéristiques du plasma traité par Intercept™ Blood System pour l’inactivation des agents pathogènes et conservé à 4 °C pendant 14 jours
41. 36 Report of World Apheresis Association registry data until June 2010
42. Enhanced Growth ofStaphylococcus aureusafter Nitric Oxide Supplementation during Simulated Extracorporeal Circulation
43. Standardized units of RBCs: is it time for implementation? [see comments]
44. Photochemical inactivation of bacteria and HIV in buffy-coat-derivedplatelet concentrates under conditions that preserve in vitro plateletfunction.
45. Pre-separation storage of whole blood: the effect of temperature on redcell 2,3-diphosphoglycerate and myeloperoxidase in plasma.
46. Storage of whole blood before separation: the effect of temperature on redcell 2,3 DPG and the accumulation of lactate.
47. Increased anticoagulant osmolality improves separation of leukocytes fromred blood cells (RBC).
48. A new apheresis procedure for the preparation of high-quality red cellsand plasma.
49. Logistics of platelet concentrateses
50. A new apheresis procedure for the preparation of high-quality red cells and plasma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.